Clinical trial
Lymphocytic B-Leukemia (B-CLL) w/Human IL-2 Gene Modified & Human CD40…
NCT00224354 · Baylor College of Medicine, Other · Withdrawn
Key facts
| NCT number | NCT00224354 |
|---|---|
| Title | Lymphocytic B-Leukemia (B-CLL) w/Human IL-2 Gene Modified & Human CD40 Ligand-Expressing Autologous Tumor Cells |
| Official title | Treatment of Chronic Lymphocytic B-Leukemia (B-CLL) With Human IL-2 Gene Modified and Human CD40 Ligand-Expressing Autologous Tumor Cells After Depletion of Regulatory T Cells |
| Acronym | CLONTAK |
| Lead sponsor | Baylor College of Medicine, Other |
| Collaborators | The Methodist Hospital Research Institute Center for Cell and Gene Therapy, Baylor College of Medicine |
| Status | Withdrawn |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | CHRONIC LYMPHOCYTIC B-LEUKEMIA |
| Intervention type | Biological, Drug |
| Interventions | IL-2 secreting and hCL4OL-expressing autologous B-CLL cells, IL-2, CD40L, ONTAK, immunotoxin dose |
| Enrollment | 0 |
| Start date | Sep 1, 2005 |
| Primary completion | Dec 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Sep 23, 2005 |
| Last update posted | May 21, 2012 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: